AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Clinical trials for AMYOTROPHIC LATERAL SCLEROSIS (ALS) explained in plain language.
Never miss a new study
Get alerted when new AMYOTROPHIC LATERAL SCLEROSIS (ALS) trials appear
Sign up with your email to follow new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New ALS drug usnoflast enters mid-stage trial to slow disease and extend life
Disease control OngoingThis study tests whether the experimental drug usnoflast can slow down ALS and help people live longer. About 240 adults with ALS will receive either usnoflast or a placebo for 36 weeks. Researchers will measure changes in daily function and survival to see if the drug makes a di…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New hope for ALS: experimental drug VHB937 enters Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called VHB937 in 251 people with early-stage ALS (symptoms started within 2 years). The goal is to see if VHB937 can slow the disease's progression, including preserving breathing and muscle function. Participants are randomly assigned to rec…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 18, 2026 12:04 UTC
-
Experimental ALS drug RJK002 enters first human safety trial
Disease control OngoingThis early-stage study tests whether a single injection of RJK002 into the spinal fluid is safe for people with ALS, a progressive nerve disease. Nine adults with ALS will receive the drug and be monitored for side effects and changes in daily function. The goal is to find a safe…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE1 • Sponsor: RJK Biopharma Ltd • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
New hope for ALS: NUZ-001 drug enters major trial
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called NUZ-001 in 160 people with ALS, a disease that weakens muscles over time. The goal is to see if the drug can slow the disease and help people live longer. Participants take the drug and are monitored for changes in movement, breathing, and survival.
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2, PHASE3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
Robotic glove offers new hope for ALS hand weakness
Symptom relief ENROLLING_BY_INVITATIONThis pilot study tests whether using a robotic glove for 20 minutes a day, five days a week, can improve grip strength, fine motor control, and quality of life in people with ALS. Five participants with a caregiver will use the glove at home for 8 weeks, with in-person and telehe…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: NA • Sponsor: Nova Southeastern University • Aim: Symptom relief
Last updated May 26, 2026 02:51 UTC
-
Brain mapping study aims to predict neurodegeneration spread
Knowledge-focused ENROLLING_BY_INVITATIONThis study uses advanced brain scans to track how diseases like frontotemporal dementia, ALS, and related conditions spread through the brain's network. Researchers will follow 645 participants, including patients and healthy volunteers, for up to 2 years. The goal is to create m…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: NA • Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated May 26, 2026 02:53 UTC